The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; 3 of the 23 sources its claims cite were checked for support.
Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome
Open accessAbstract
Background The characteristics and the clinical course of antiphospholipid syndrome (APS) in high-risk patients that are positive for all three recommended tests that detect the presence of antiphospholipid (aPL) antibodies have not been described. Methods This retrospective analysis of prospectively collected data examined patients referred to Italian Thrombosis Centers that were diagnosed with definite APS and tested positive for aPL [lupus anticoagulant (LA), anti-cardiolipin (aCL), and anti-beta2-glycoprotein I (beta2GPI) antibodies]. Laboratory data were confirmed in a central reference laboratory. Results One hundred and sixty patients were enrolled in this cohort study. The qualifying events at diagnosis were venous thromboembolism (76 cases; 47.5%), arterial thromboembolism (69 cases; 43.1%) and pregnancy morbidity (11 cases; 9.7%). The remaining four patients (2.5%) suffered from catastrophic APS. The cumulative incidence of thromboembolic events in the follow-up period was 12.2% (95% CI, 9.6-14.8) after 1 year, 26.1% (95% CI, 22.3-29.9) after 5 years and 44.2% (95% CI, 38.6-49.8) after 10 years. This was significantly higher in those patients not taking oral anticoagulants as compared with those on treatment (HR=2.4 95% CI 1.3-4.1; P<0.003). Major bleeding associated with oral anticoagulant therapy was low (0.8% patient/years). Ten patients died (seven were cardiovascular deaths). Conclusions Patients with APS and triple positivity for aPL are at high risk of developing future thromboembolic events. Recurrence remains frequent despite the use of oral anticoagulants, which significantly reduces the risk of thromboembolism.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In 160 patients with definite antiphospholipid syndrome (APS) and triple positivity for lupus anticoagulant, anti-cardiolipin, and anti-β2-glycoprotein I antibodies, thromboembolic recurrence was frequent, with a cumulative incidence of 44.2% at 10 years. Oral anticoagulant treatment was associated with a significantly lower risk of recurrent thromboembolism, while major bleeding on anticoagulation was low.
Key findings
- During follow-up, 55 of 160 patients (34.4%) had a thromboembolic event (25 venous, 30 arterial); cumulative incidence was 12.2% (95% CI 9.6–14.8) at 1 year, 26.1% (95% CI 22.3–29.9) at 5 years, and 44.2% (95% CI 38.6–49.8) at 10 years.
- Oral anticoagulant status was the only predictor of thromboembolic events in multivariate Cox analysis: events occurred in 36/123 anticoagulated patients versus 19/37 non-anticoagulated patients, with HR 2.4 (95% CI 1.3–4.1; P < 0.003) for not taking oral anticoagulants; cumulative incidence was significantly higher in untreated patients (P = 0.002).
- Major bleeding was low: 8 major bleeding events, 7 in patients on oral anticoagulants (0.8% patient/years); there were 10 deaths (0.8% patients/years; 7 cardiovascular, 3 non-cardiovascular).
- Recurrence did not depend on the qualifying event: 10-year cumulative incidence was 45% for venous, 47% for arterial, and 37% for pregnancy morbidity as the qualifying event (P = ns).
Methods
- Retrospective analysis of prospectively collected data from Italian Thrombosis Centers, including 160 patients with definite APS and triple positivity for LA, aCL, and anti-β2GPI antibodies, confirmed in a central reference laboratory; inclusion required LA and anti-β2GPI positivity and aCL > 40 GPL and/or > 40 MPL units.
- Observation period from earliest diagnosis (March 1989) to March 2009; outcomes included objectively diagnosed thromboembolic events, major bleeding, and death.
- Kaplan-Meier survival analysis estimated cumulative incidence of thromboembolic events; log-rank tests compared groups; Cox regression identified predictors of the primary endpoint.
Limitations
- The paper does not include a formal limitations section; evident limitations include the observational, non-randomized treatment comparison (123 patients received long-term oral anticoagulants versus 37 who did not), so treatment effects may be confounded.
- The cohort was selected from Thrombosis Centers and restricted to triple-positive APS patients with aCL > 40 units, limiting generalizability to other APS laboratory profiles or lower-risk populations.
- Follow-up attrition was substantial: only 23 patients (14.4%) completed 10 years; pregnancy morbidity was uncommon (11 cases), and the reported percentage differs between the abstract (9.7%) and Results/Table 1 (6.9%).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
24 Own result · 11 No full text of the sources · 6 Own interpretation · 4 Own method · 3 Sources not found · 1 Supported so far · 1 Partly supported · 1 Couldn’t confirm · 1 Not checked yet · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This selected cohort of patients differed from the large cohort described by Cervera et al. [25,26] in several aspects.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
- Not checked — no full text of the sourcecites [25] source
- Supportedcites [26] source
The Patient selection section describes a multicentre cohort of 1,000 unselected patients with antiphospholipid syndrome. The citation identifies the large Cervera et al. cohort used for comparison; the assertion that the citing authors’ cohort differs is their own comparison. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As there is currently no evidence to support the superiority of oral anticoagulant therapy over antiplatelet therapy [15], antiplatelet drugs are generally recommended after an episode of stroke.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
- Partly supportedcites [15] sourceExperimental — accuracy not yet measured
The COMMENT section reports that warfarin was not associated with fewer thrombo-occlusive events than aspirin in the studied stroke cohort. That supports the comparison, but the citing sentence generalizes it to all oral anticoagulants and antiplatelet therapies; the paper does not establish that broader claim. No page number is available in the supplied copy. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Less than half of the patients reported by Cervera et al. were LA positive.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
- Not checked — no full text of the sourcecites [25] source
- Could not verifycites [26] sourceExperimental — accuracy not yet measured
The Laboratory studies section says LA activity was tested but gives no positivity rate. The General characteristics section says the cohort’s immunological findings were reported elsewhere. Searches for LA prevalence and a percentage below 50% found no figure in our copy (page numbers unavailable). (LLM, conf=0.75)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The remaining four patients (2.5%) suffered from catastrophic APS.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Major bleeding associated with oral anticoagulant therapy was low (0.8% patient/years).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Our data come close to the data from Cervera et al., if we only considered primary APS patients (female/male ratio drops to 3.5:1) [25].”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
- Not checked — no full text of the sourcecites [25] source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Our findings do not confirm the findings of previous studies [23,27] that have suggested that the recurrence of an event is more likely to occur in the same vascular district (i.e.venous or arterial).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The qualifying event at diagnosis was VTE in 76 cases (47.5%), arterial thromboembolism in 69 cases (43.1%) and pregnancy morbidity in 11 cases (6.9%).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Results
plainn = 69- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The qualifying event at diagnosis did not predict the type of recurrence (arterial or venous).”
- Also stated in: § Thromboembolic events during the followup period · plain
“The incidence of events during follow-up was independent of the clinical manifestations at diagnosis.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
plainn = 160- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Thromboembolic events during the followup period · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The cumulative incidence of thromboembolic events in the follow-up period was 12.2% (95%CI, 9.6-14.8)after 1 year, 26.1% (95%CI, 22.3-29.9)after 5 years and 44.2% (95%CI, 38.6-49.8)after 10 years.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The quote only partly states this claim. 3
- It may state two separate claims as one. 17
- Probably not a substantial claim. 6
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One hundred and sixty patients were enrolled in this cohort study.”
- Also stated in: § Results · plain
“Thus, 160 patients with three positive APS tests were enrolled in this cohort study.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
plainn = 160- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Ten patients died (seven were cardiovascular deaths).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
plainn = 10- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The qualifying event at diagnosis was VTE in 76 cases (47.5%), arterial thromboembolism in 69 cases (43.1%) and pregnancy morbidity in 11 cases (6.9%).”
- Also stated in: § Abstract · plain
“The qualifying events at diagnosis were venous thromboembolism (76 cases; 47.5%), arterial thromboembolism (69 cases; 43.1%) and pregnancy morbidity (11 cases; 9.7%).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Results
plainn = 11- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § Abstract · plain
In the paper
“We had more male patients (29% vs. 18%) and primary APS cases (62% vs. 53%).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
- Not checked — no full text of the sourcecites [25] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The number of enrolled patients with obstetric complications alone was low (9.7%), highlighting that the majority of female patients with triple positivity in laboratory tests suffer from thromboembolic events [22].”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were eight major bleeding events -seven in patients on oral anticoagulants (0.8% patient/years) -and 10 deaths during follow-up (0.8% patients/years; seven were cardiovascular and three were non-cardiovascular deaths).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Major bleeding and death
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in Fig. 2, the cumulative incidence of events after 10 years was 45%, 47% and 37% for venous, arterial and pregnancy morbidity as a qualifying event, respectively (P = ns).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Thromboembolic events during the followup period
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Out of the 160 patients, 55 (34.4%) had a thromboembolic event during the follow-up period; 25 were VTE and 30 were arterial thromboembolism.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Thromboembolic events during the followup period
plainn = 160- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 189 patients considered for this study, 29 were excluded; 11 because the laboratory data were not confirmed in the reference laboratory and 18 for having both GPL and MPL aCL titers of < 40 units.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Results
plainn = 189- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Subsequent thromboembolism occurred in 36 (16 VTE and 20 ATE) out of 123 anticoagulated patients [median International normalized ratio (INR) at the time of event 2.3], and in 19 (9 VTE and 10 ATE) out of the 37 non-anticoagulated patients.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Thromboembolic events during the followup period
plainn = 123- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were eight major bleeding events -seven in patients on oral anticoagulants (0.8% patient/years) -and 10 deaths during follow-up (0.8% patients/years; seven were cardiovascular and three were non-cardiovascular deaths).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Major bleeding and death
plainn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Out of 160 patients, 123 received long-term oral anticoagulant treatment during the entire follow-up period, whereas 37 did not (13 did not take anticoagulants and 24 took aspirin alone).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Thromboembolic events during the followup period
plainn = 160- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One hundred and thirty-one (81.9%) patients completed the 1year follow-up, 76 (47.5%) completed 5 years and 23 (14.4%) completed 10 years of follow-up.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Thromboembolic events during the followup period
plainn = 160- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mean follow-up was 6.0 (± 4.6) years (range 0.3-20 years).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Thromboembolic events during the followup period
plainn = 160- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Many clinical studies on APS have included patients with different laboratory profiles, and consequently, the results may lack consistency [14][15][16][17].”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Introduction
What the sources say
- Not matchedcites [14][15][16][17]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As just one positive test is sufficient for APS diagnosis, there is a substantial risk of diagnosing APS in patients with either one false-positive test or with antibodies that recognize a target that is irrelevant to the syndrome.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Introduction
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Oral anticoagulants are recommended after a first episode of VTE [28] to prevent recurrence [29][30][31][32].”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
- Not checked — no full text of the sourcecites [28] source
- Not matchedcites [29][30][31][32]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“To confirm triple positivity for aPL, and to validate the laboratory diagnosis, patient plasma from each center was also tested in a reference laboratory.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Study design and population
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“However, these tests are poorly standardized, which leads to low sensitivity [2][3][4].”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Introduction
What the sources say
- Not matchedcites [2][3][4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, data were confirmed in all patients and tests were repeated in recurrent cases or each year in the majority of patients.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Both the type and site of any thromboembolic events at diagnosis were demonstrated objectively.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Data collection and clinical features at diagnosis
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Recurrence remains frequent despite the use of oral anticoagulants, which significantly reduces the risk of thromboembolism.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
In the paper
“In contrast, multiple positivity shows a marked association with thromboembolic events and severe pregnancy morbidity [8][9][10][11][12][13].”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Introduction
What the sources say
- Not matchedcites [8][9][10][11][12][13]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Oral anticoagulant therapy significantly reduces recurrent thromboembolism, although it might prove insufficient in some cases.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
No prior study has described the characteristics and clinical course of APS in high-risk patients positive for all three recommended aPL tests.
“To our knowledge, no study has reported the characteristics and clinical course of a homogenous group of APS patients that are positive in all three laboratory diagnostic tests.”
“The characteristics and the clinical course of antiphospholipid syndrome (APS) in high-risk patients that are positive for all three recommended tests that detect the presence of antiphospholipid (aPL) antibodies have not been described.”
The paper relies on this without support.
This is the first large-scale study to examine the clinical course of a homogeneous cohort of APS patients with full positive laboratory profile.
“To our knowledge, this is the first large-scale study looking at the clinical course of a homogenous cohort of APS patients with full positive laboratory profile.”
“which to our knowledge is the first to examine patients that are positive for APS as determined by three separate tests”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite long-term anticoagulation with vitamin K antagonists, patients with thrombotic PAPS remain at substantial risk of recurrent thrombotic events, with cumulative recurrence rates approaching 20% at 5 years in observational cohorts [2].”
From Hydroxychloroquine as an Adjunct Therapy for Secondary Thrombosis Prevention in Primary Antiphospholipid Syndrome: A Systematic Review and Meta-analysis (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The incidence was significantly higher in patients not taking OAs (HR 2.4, 95% CI 1.3-4.1,P < 0.003) [11].”
From Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients (2013) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“aPL profiling also involves consideration of antibody titers since higher titers are associated with higher risk [7,8,30,31].”
From Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients positive for the combination of LAC, antiβ 2GPI, and anti-CL antibodies,theso-called triple-positive patients, exhibit a high risk for developing a first thrombotic event and recurrence of thrombosis. 8,9”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“andpatientspositiveforallthree aPLs are identified as individuals at high risk for a first clinical event and for recurrence. 8,9”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [8]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“triple positivity (all 3 tests positive) is associated with thrombosis and identifies high-risk patients with aPL syndrome (APS).6,7”
From Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study (2011) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“At 1 year, the cumulative incidence of thromboembolic events was 12.2%, and at 10 years it was 44.2%, in a retrospective study in APS patients [11].”
From Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients (2013) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Of note is that many studies on triple positivity merely report patients as being positive for LA without assessing dRVVT and APTT results separately [10,[23][24][25][26][27][28][29], or even use only 1 assay [7,8,12].”
From Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“The qualifying events at diagnosis were venous thromboembolism (76 cases; 47.5%), arterial thromboembolism (69 cases; 43.1%) and pregnancy morbidity (11 cases; 9.7%).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
Reported 9.7 · recomputed 6.875
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Other | 34 (19.3) |”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
Reported 19.3 · recomputed 21.25
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Table 1 Demographic and clinical characteristics at diagnosis of 160 highrisk APS patients* | Characteristics | | | --- | --- | | Age years | 41.1 ± 15.0 | | Female -no. (%) | 113 (70.6) | | APS-related event at diagnosis -no. (%) | | | VTE | 76 (47.5) | | Arterial Thrombosis | 69 (43.1) | | Obstetric complications | 11 (6.9) | | Catastrophic APS | 4 (2.5) | | Autoimmune disorders -no.(%) | | | SLE | 33 (18.8) |”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
Reported 18.8 · recomputed 20.625
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Risk for arterial thrombosis -no. (%) | 87 (49.4) |”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
Reported 49.4 · recomputed 54.375
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Risk for venous thrombosisà -no. (%) | 71 (40.3) |”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
Reported 40.3 · recomputed 44.375
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Cervera, R., Piette, J., Font, J., Khamashta, M. A., Shoenfeld, Y., Camps, M. T., Jacobsen, S., Lakos, G., Tincani, A., Kontopoulou‐Griva, I., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10187 · Cited by 2,156
Antithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M. M., Tapson, V. F., & Weg, J. G. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,035
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Antithrombotic Therapy for Venous Thromboembolic Disease
Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.401s · Cited by 1,249
Kearon, C., Gent, M., Hirsh, J., Weitz, J. I., Kovacs, M. J., Anderson, D. R., Turpie, A. G. G., Green, D., Ginsberg, J. S., Wells, P. S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,057
Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramón, E., Buonaiuto, V, Jacobsen, S., Zeher, M. M., Tarr, T., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204838 · Cited by 974
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 972
Crowther, M. A., Ginsberg, J. S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., Laskin, C., Fortin, P., Anderson, D., Kearon, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035241 · Cited by 919
Asherson, R. A., Cervera, R., de Groot, P. G., Erkan, D., Boffa, M., Pietté, J. C., Khamashta, M. A., Shoenfeld, Y., & Catastrophic Antiphospholipid Syndrome Registry Project Group (2003) · Lupus · doi:10.1191/0961203303lu394oa · Cited by 863
Cited by
Sorted by citations
Items 101–200 of 629
Vikerfors, A., Johansson, A.-B., Gustafsson, J. T., Jonsen, A., Leonard, D., Zickert, A., Nordmark, G., Sturfelt, G., Bengtsson, A., Ronnblom, L., et al. (2013) · Rheumatology · doi:10.1093/rheumatology/kes252 · Cited by 51
The antiphospholipid syndrome: still an enigma
Chaturvedi, S., & McCrae, K. R. (2015) · Hematology · doi:10.1182/asheducation-2015.1.53 · Cited by 51
Misasi, R., Capozzi, A., Longo, A., Recalchi, S., Lococo, E., Alessandri, C., Conti, F., Valesini, G., & Sorice, M. (2015) · Journal of Immunology Research · doi:10.1155/2015/858542 · Cited by 51
Vandevelde, A., Chayouâ, W., de Laat, B., Moore, G. W., Musiał, J., Zuily, S., Wahl, D. G., & Devreese, K. M. J. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15785 · Cited by 52
Martinelli, I., Abbattista, M., Bucciarelli, P., Tripodi, A., Artoni, A., Gianniello, F., Novembrino, C., & Peyvandi, F. (2018) · Haematologica · doi:10.3324/haematol.2017.185132 · Cited by 51
“This condition is a severe acquired thrombophilia associated with an increased risk of venous and arterial thrombosis and adverse pregnancy outcome.(1) The presence of aPL and clinical manifestations define the antiphospholipid syndrome (aPS).”
BackgroundUse of direct oral anticoagulants in antiphospholipid syndrome
Cohen, H., Efthymiou, M., & Isenberg, D. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14017 · Cited by 69
Complement and the prothrombotic state
Schmidt, C. Q., Schrezenmeier, H., & Kavanagh, D. (2021) · Blood · doi:10.1182/blood.2020007206 · Cited by 49
The lupus anticoagulant: results from 2257 patients attending a high-risk pregnancy clinic
Clark, C. A., Davidovits, J., Spitzer, K. A., & Laskin, C. A. (2013) · Blood · doi:10.1182/blood-2013-02-485839 · Cited by 49
The Lupus Anticoagulant Paradox
Molhoek, J. E., de Groot, P. G., & Urbanus, R. T. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1606190 · Cited by 50
Cohen, H., Mackie, I. J., & Devreese, K. M. J. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14560 · Cited by 48
Sciascia, S., Baldovino, S., Schreiber, K. I., Solfietti, L., Radin, M., Cuadrado, M. J., Menegatti, E., Erkan, D., & Roccatello, D. (2016) · Clinical and Molecular Allergy · doi:10.1186/s12948-016-0043-2 · Cited by 48
“However, it is worth noting that compliance with regards to anticoagulation therapy was not specified [55].”
BackgroundOrtel, T. L., Meleth, S., Catellier, D., Crowther, M. A., Erkan, D., Fortin, P. R., Garcia, D. A., Haywood, N., Kosinski, A. S., Levine, S. R., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14936 · Cited by 46
Pengo, V., Ruffatti, A., Tonello, M., Hoxha, A., Bison, E., Denas, G., Padayattil Jose, S., Zoppellaro, G., Bracco, A., & Banzato, A. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.04.031 · Cited by 47
“Patients with triple laboratory profile are at high risk of both developing thrombosis or having recurrences; double and single positive patients are at lower or at no risk of having events [2].”
BackgroundSelf-citationMoore, G. W., Jones, P. O., Platton, S., Hussain, N., White, D., Thomas, W., Rigano, J., Pouplard, C., Gray, E., & Devreese, K. M. J. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15438 · Cited by 47
López-Pedrera, C., Barbarroja, N., Patiño-Trives, A. M., Collantes‐Estévez, E., Aguirre, M. A., & Pérez‐Sánchez, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00764 · Cited by 46
“Subjects positive for LA, higher titers of anti-CL, and anti-ß2GPI antibodies (known as “triple positives”), have the highest risks for thrombosis (15).”
BackgroundBała, M. M., Celińska‐Löwenhoff, M., Szot, W., Padjas, A., Kaczmarczyk, M., Świerz, M. J., & Undas, A. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012169.pub3 · Cited by 46
Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome
Devreese, K. M. J., Zuily, S., & Meroni, P. L. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100134 · Cited by 51
“Isolated positivity of LA, in absence of aCL and aβ2GPI, is regarded as a lower risk factor [4].”
BackgroundAnticoagulant Therapy in Patients with Antiphospholipid Syndrome
Capecchi, M., Abbattista, M., Ciavarella, A., Uhr, M., Novembrino, C., & Martinelli, I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236984 · Cited by 51
“Recurrent thrombosis is common in patients with APS, even despite antithrombotic prophylaxis (recurrence rate of 30–40% during long term follow-up) [22].”
BackgroundLaboratory Diagnostics in Thrombophilia
Hart, C., & Linnemann, B. (2019) · Hämostaseologie · doi:10.1055/s-0039-1677840 · Cited by 49
Management of Recurrent Thrombosis in Antiphospholipid Syndrome
Nalli, C., Andréoli, L., Casu, C., & Tincani, A. (2014) · Current Rheumatology Reports · doi:10.1007/s11926-013-0405-4 · Cited by 43
Bertero, M., Bazzan, M., CARIGNOLA, R., Montaruli, B., Silvestro, E., Sciascia, S., Vaccarino, A., Baldovino, S., & Roccatello, D. (2012) · Lupus · doi:10.1177/0961203312446974 · Cited by 44
Antiphospholipid syndrome: an update
Merashli, M., Noureldine, M. H. A., Uthman, I. W., & Khamashta, M. A. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12449 · Cited by 44
Mosteirín, N. F., Comet, L. S., Osuna, C. S., Villas, J. M. C., & Marcó, J. (2017) · Lupus · doi:10.1177/0961203317703493 · Cited by 43
Zuily, S., Clerc‐Urmès, I., Bauman, C., ANDRADE, D. C. O. D., Sciascia, S., Pengo, V., Tektonidou, M. G., Ugarte, A., Gerosa, M., Belmont, M. H., et al. (2020) · Lupus · doi:10.1177/0961203320940776 · Cited by 44
“aPL profile, especially triple-aPL positivity, is considered as the most clinically significant laboratory profile that exposes patients to a higher risk for developing aPL-related clinical events.(12) Furthermore, the additive impact of CVD risk factors on the development of thrombosis in aPL-positive patients(13) is…”
BackgroundSelf-citationMeroni, P. L., & Borghi, M. O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.726820 · Cited by 46
“, LA, aCL, anti-b2GPI) represents a further risk factor in the socalled tetrapositive patients (6, 49).”
BackgroundRecurrent Venous Thromboembolism: What Is the Risk and How to Prevent It
Palareti, G. (2012) · Scientifica · doi:10.6064/2012/391734 · Cited by 44
“%) observed in a recent inception cohort of patients with a �rst episode of symptomatic VTE who discontinued anticoagulant therapy [40].”
BackgroundKolyada, A. Y., Porter, A., & Beglova, N. (2013) · Blood · doi:10.1182/blood-2013-08-520882 · Cited by 42
“Thrombotic events in APS nearly equally occur in veins and arteries, and about 30% of patients with thrombosis are men.(4-7) Thrombosis in APS correlates with the presence of antibodies to b2-glycoprotein I (b2GPI).”
Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome
Iwaniec, T., Kaczor, M. P., Celińska‐Löwenhoff, M., Polański, S., & Musiał, J. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.02.019 · Cited by 43
“In double- and single-positive patients the risk of thrombotic complications is uncertain [12, 30].”
BackgroundHypercoagulable states in arterial and venous thrombosis: When, how, and who to test?
Carroll, B., & Piazza, G. (2018) · Vascular Medicine · doi:10.1177/1358863x18755927 · Cited by 44
Hollerbach, A., Müller‐Calleja, N., Ritter, S., Häuser, F., Canisius, A., Orning, C., Jurk, K., & Lackner, K. J. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1685453 · Cited by 43
Pengo, V., Ruiz‐Irastorza, G., Denas, G., Andréoli, L., Khamashta, M. A., & Tincani, A. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.10.016 · Cited by 40
Self-citationManaging thromboembolic risk in patients with hereditary and acquired thrombophilias
Moran, J. P., & Bauer, K. A. (2020) · Blood · doi:10.1182/blood.2019000917 · Cited by 42
Saraiva, S. D. S., Custódio, I., Mazetto, B. D. M., Colella, M. P., Paula, E. V. D., Appenzeller, S., Annichino-Bizzachi, J., & Orsi, F. A. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.10.029 · Cited by 40
Antiphospholipid Syndrome Clinical Research Task Force Report
Erkan, D., Derksen, R. H. W. M., Levy, R. A., Machin, S. J., Ortel, T. L., Pierangeli, S. S., Roubey, R. A. S., & Lockshin, M. D. (2011) · Lupus · doi:10.1177/0961203310395053 · Cited by 42
Cessation of oral anticoagulants in antiphospholipid syndrome
Comarmond, C., Jégo, P., Veyssier-Belot, C., Marié, I., MEKINIAN, A., Elmaleh-Sachs, A., Leroux, G., Saadoun, D., Oziol, E., Fraisse, T., et al. (2017) · Lupus · doi:10.1177/0961203317699285 · Cited by 39
The antiphospholipid syndrome – often overlooked cause of vascular occlusions?
Svenungsson, E., & Antovič, A. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13022 · Cited by 39
Antiphospholipid syndrome, antiphospholipid antibodies, and stroke
Mittal, P., Quattrocchi, G., Tohidi‐Esfahani, I., Sayar, Z., Chandratheva, A., & Cohen, H. (2022) · International Journal of Stroke · doi:10.1177/17474930221150349 · Cited by 41
Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome
Les, Í., Ruiz‐Irastorza, G., & Khamashta, M. A. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1304720 · Cited by 38
Tonello, M., Mattia, E., Favarò, M., Ross, T. D., Calligaro, A., Salvan, E., Hoxha, A., Fedrigo, M., & Ruffatti, A. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.03.006 · Cited by 38
Self-citationAPS - Diagnostics and challenges for the future
Pengo, V., Bison, E., Zoppellaro, G., Jose, S. P., Denas, G., Hoxha, A., Ruffatti, A., & Banzato, A. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.028 · Cited by 37
Self-citationLaboratory Diagnostics of Antiphospholipid Syndrome
Bison, E., Denas, G., Jose, S., Zoppellaro, G., Banzato, A., & Pengo, V. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1601331 · Cited by 37
Self-citationJiang, X., Du, Y., Cheng, C., Denas, G., Zhou, Y., Wu, T., Zhang, Y., Han, Z.-Y., Pengo, V., & Jing, Z. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1692428 · Cited by 40
Self-citationIsert, M., Miesbach, W., Schüttfort, G., Weil, Y., Tirneci, V., Kasper, A., Weber, A., Lindhoff‐Last, E., Herrmann, E. M., & Linnemann, B. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2374-3 · Cited by 35
“the presence of lupus anticoagulant, anticardiolipin and anti-beta-2-glycoprotein-I antibodies) and reported a cumulative incidence of 29 % for subsequent thromboembolism among APS patients during long-term oral anticoagulant treatment [3].”
BackgroundThe challenges of lupus anticoagulants
Chighizola, C. B., Raschi, E., Banzato, A., Borghi, M. O., Pengo, V., & Meroni, P. L. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1140034 · Cited by 36
Self-citationDiagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective
Pengo, V., & Denas, G. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.07.011 · Cited by 37
Self-citationTesting for antiphospholipid antibodies: Advances and best practices
Devreese, K. M. J. (2020) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13195 · Cited by 39
Yin, D., de Groot, P. G., Ninivaggi, M., Devreese, K. M. J., & de Laat, B. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1344-4271 · Cited by 36
Favaloro, E. J., & Wong, R. C. W. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.064 · Cited by 36
Direct oral anticoagulants in hypercoagulable states
Kunk, P. R., Brown, J. T., McShane, M., Palkimas, S., & Macik, B. G. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1420-x · Cited by 35
“lupus anticoagulant, anti-β2 glycoprotein and anti-cardiolipin antibodies), the risk of recurrent thrombi while on therapy can be as high as 26 % in 5 years [6].”
BackgroundManagement of Thrombotic Antiphospholipid Syndrome
Chighizola, C. B., Raimondo, M. G., & Meroni, P. L. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1597282 · Cited by 35
Sciascia, S., Radin, M., Cecchi, I., Bertolaccini, M. L., Bertero, M. T., Rubini, E., Vaccarino, A., Bazzan, M., Giachino, O., Baldovino, S., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/kez596 · Cited by 35
How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome
Cohen, H., & Isenberg, D. A. (2020) · Blood · doi:10.1182/blood.2020004942 · Cited by 35
“8% in a retrospective cohort study on triple aPL-positive APS patients.(16) In the past decade, direct oral anticoagulants (DOACs) have been introduced as a potential alternative to VKAs.”
BackgroundVerrou, K., Sfikakis, P. P., & Tektonidou, M. G. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102978 · Cited by 34
Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome
Wijetilleka, S., Scoble, T., & Khamashta, M. A. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328354ae8c · Cited by 33
“There is strong evidence to suggest that patients with arterial thrombosis succumb to recurrent events [45] so it would be intuitive to raise the INR to above 3.”
BackgroundNew oral anticoagulants in thrombotic antiphospholipid syndrome
Chighizola, C. B., Moia, M., & Meroni, P. L. (2014) · Lupus · doi:10.1177/0961203314540968 · Cited by 34
Ruffatti, A., Silvestro, G. D., Marson, P., Tonello, M., Calligaro, A., Favarò, M., Ross, T. D., Hoxha, A., Mattia, E., & Pengo, V. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.07.001 · Cited by 35
Self-citationYin, D., de Laat, B., Devreese, K. M. J., & Kelchtermans, H. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.06.011 · Cited by 36
Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome
Pengo, V. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14896 · Cited by 34
Self-citationHow to Interpret Antiphospholipid Laboratory Tests
Devreese, K. M. J. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00916-5 · Cited by 36
High Prevalence of Prothrombotic Abnormalities in Multifocal Osteonecrosis
Gómez-Puerta, J. A., Peris, P., Reverter, J. C., Espinosa, G., Martinez-Ferrer, A., Monegal, A., Ruiz, J. M. M., Tàssies, D., & Guañabens, N. (2013) · Medicine · doi:10.1097/md.0000000000000007 · Cited by 35
“Currently, it is well known that patients with triple positivity for aPL (LA, aCL, and anti-A2-glycoprotein I) are considered to have a higher risk for thrombosis.(49) In fact, these patients may develop recurrent thrombotic episodes, despite the use of oral anticoagulants.”
BackgroundRecurrent Miscarriage, Antiphospholipid Antibodies and the Risk of Thromboembolic Disease
Martínez‐Zamora, M. Á., Cervera, R., & Balasch, J. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-012-8316-0 · Cited by 33
“No single predominant risk factor has been identified, although, according to the different studies, possessing a combination of cardiovascular risk factors may increase the occurrence of arterial thrombosis [77], and multiple positivity in tests, exploring the presence of aPL, may be associated with thromboembolic ev…”
BackgroundCurrent Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review
Bradáčová, P., Slavík, L., Úlehlová, J., Skoumalová, A., Ullrychová, J., Procházková, J., Hluší, A., Manukyan, G. P., & Kriegová, E. (2021) · Biomedicines · doi:10.3390/biomedicines9020166 · Cited by 33
Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome
Sciascia, S., Radin, M., Bazzan, M., & Roccatello, D. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1596-2 · Cited by 32
Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation
Forastiero, R. R. (2014) · Lupus · doi:10.1177/0961203314531635 · Cited by 32
Rupa‐Matysek, J., Gil, L., Wojtasińska, E., et al. (2014) · Rheumatology International · doi:10.1007/s00296-014-2996-0 · Cited by 32
“Triple positivity for Abs, which is described by Vitorio Pengo’s group as being associated with high thrombotic recurrence rates in Italian APS patients, is also associated with high thrombotic recurrence rates in our cohort [22, 23].”
BackgroundTherapeutic apheresis during pregnancy: A single center experience
Colpo, A., Marson, P., Pavanello, F., Tison, T., Gervasi, M. T., Zambon, A., Ruffatti, A., Silvestro, G. D., & Hoxha, A. (2019) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2019.07.009 · Cited by 32
Self-citationGoodman, S. M., & Bass, A. R. (2018) · BMC Rheumatology · doi:10.1186/s41927-018-0008-9 · Cited by 31
Yin, D., Chayouâ, W., Kelchtermans, H., de Groot, P. G., Moore, G. W., Gris, J., Zuily, S., Musiał, J., de Laat, B., & Devreese, K. M. J. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14682 · Cited by 31
Mauracher, L., Krall, M., Roiß, J., Hell, L., Koder, S., Hofbauer, T. M., Gebhart, J., Hayden, H., Brostjan, C., Ay, C., et al. (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa532 · Cited by 31
Utility of current thrombophilia screening in young patients with stroke and TIA
Alakbarzade, V., Taylor, A. E., Scully, M., Simister, R. J., & Chandratheva, A. (2018) · Stroke and Vascular Neurology · doi:10.1136/svn-2018-000169 · Cited by 30
“Acute ischaemic stroke, n (%) 36 (72) 16 (32) 20 (40)”
Cheng, C., Zhang, Y., Denas, G., Du, Y., Jing, Z., & Pengo, V. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-018-02021-z · Cited by 30
Self-citationSavelli, S., Roubey, R. A. S., Kitzmiller, K. J., Zhou, D., Nagaraja, H. N., Mulvihill, E., Barbar-Smiley, F. A., Ardoin, S. P., Wu, Y. L., & Yu, C. Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00885 · Cited by 33
“Human subjects with triple positivity for all three groups of aPL appeared to be at high risk to experience recurrent thromboembolic events (9).”
BackgroundOgata, Y., Fujieda, Y., Sugawara, M., Sato, T., Ohnishi, N., Kono, M., Kato, M., Oku, K., Amengual, O., & Atsumi, T. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa542 · Cited by 28
Laboratory testing for antiphospholipid syndrome
Pengo, V., Banzato, A., Bison, E., Denas, G., Zoppellaro, G., Bracco, A., Jose, S. P., Hoxha, A., & Ruffatti, A. (2016) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12507 · Cited by 29
“Recently, other tests have been proposed for the diagnosis of APS.”
BackgroundInfluentialSelf-citationUnexpected, isolated activated partial thromboplastin time prolongation: A practical mini‐review
Rasmussen, K. L., Philips, M., Tripodi, A., & Goetze, J. P. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13394 · Cited by 29
Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome
Kwon, O. C., Park, Y., & Park, M. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keab410 · Cited by 29
Galli, M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03689.x · Cited by 29
Zhang, S., Wu, Z., Chen, S., Li, J., Wen, X., Li, L., Zhang, W., Zhao, J., Zhang, F., & Li, Y. (2016) · Scientific Reports · doi:10.1038/srep23839 · Cited by 29
Dilemmas in the diagnosis and management of antiphospholipid syndrome
Manning, J. E., & Arachchillage, D. J. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.03.027 · Cited by 34
Diagnosis and therapy of antiphospholipid syndrome
Pengo, V., Denas, G., Jose, S. P., Zoppellaro, G., Bison, E., Banzato, A., Hoxha, A., & Ruffatti, A. (2015) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3051 · Cited by 28
Self-citationBazzan, M., Vaccarino, A., Stella, S., Bertero, M., CARIGNOLA, R., Montaruli, B., Roccatello, D., & Shoenfeld, Y. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.11.007 · Cited by 28
“[9] is an ambispective, multicenter study.”
BackgroundInfluentialMineo, C., Lanier, L., Jung, E.-J., Sengupta, S., Ulrich, V., Sacharidou, A., Tarango, C., Osunbunmi, O., Shen, Y.-M. P., Salmon, J. E., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158757 · Cited by 28
“In addition, despite oral anticoagulation therapy, individuals with a laboratory diagnosis of APS have a 44% likelihood of suffering a thrombotic event within 10 years [63].”
Shi, H., Teng, J., Sun, Y., Wu, X., Hu, Q., Liu, H.-L., Cheng, X., Yin, Y., Ye, J., Chen, P. P., et al. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3549-1 · Cited by 28
“There is growing evidence that patients with combined aPL positivity are associated with increasing thrombotic risk [33, 34].”
BackgroundDirect oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?
Rességuier, A.-S., Pereira, B., Rieu, V., Guenno, G. L., Grobost, V., & Ruivard, M. (2017) · Lupus · doi:10.1177/0961203317701841 · Cited by 28
Shiber, S., & Molad, Y. (2014) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000218 · Cited by 28
Torricelli, A., Lopes, M. R. U., Bonfá, E., et al. (2020) · Lupus · doi:10.1177/0961203320901598 · Cited by 28
Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?
Weitz, J. I., Prandoni, P., & Verhamme, P. B. (2020) · TH Open · doi:10.1055/s-0040-1721735 · Cited by 28
Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?
Mormile, I., Granata, F., Punziano, A., de Paulis, A., & Rossi, F. W. (2021) · Biomedicines · doi:10.3390/biomedicines9020132 · Cited by 28
“The triple-positive population of LA, aCL, and anti-β2GPI has been regarded as the highest risk group for TEs and poor neonatal outcomes [16,17].”
BackgroundNiznik, S., Rapoport, M. J., Avnery, O. H., Lubetsky, A., Yahia, S. H., Ellis, M. H., & Agmon‐Levin, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.843718 · Cited by 27
“showed that the triple positivity of aPL is predictive of worst outcomes (8).”
BackgroundResultInfluentialDel Ross, T., Ruffatti, A., Cuffaro, S., Tonello, M., Calligaro, A., Favaro, M., Facchinetti, M., Hoxha, A., & Punzi, L. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.08.019 · Cited by 27
Self-citationCeccarelli, F., Chighizola, C. B., Finazzi, G., Meroni, P. L., & Valesini, G. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.10.014 · Cited by 27
Grimaud, F., Yelnik, C., de Chambrun, M. P., Amoura, Z., Arnaud, L., Costedoat-Chalumeau, N., HACHULLA, E., Lambert, M., Roriz, M., Sibilia, J., et al. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key437 · Cited by 27
ANDRADE, D. C. O. D., Cervera, R., Cohen, H., Crowther, M. A., Cuadrado, M. J., Canaud, G., Garcia, D. A., Gerosa, M., Ortel, T. L., Pengo, V., et al. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_18 · Cited by 26
Self-citationCáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Carmona, L., et al. (2019) · Reumatología Clínica · doi:10.1016/j.reuma.2018.11.003 · Cited by 26
Foret, T., Dufrost, V., du Mont, L. S., et al. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keab853 · Cited by 26
Clinical Management of Thrombotic Antiphospholipid Syndrome
Tumian, N. R., & Hunt, B. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030735 · Cited by 45
“The presence of all three, LA, IgG and/or IgM anti-β2GP,I and IgG and/or IgM aCL positivity, known as ‘triple aPL-positivity,’ is particularly associated with a high risk of thrombosis based on the cumulative incidence of thromboembolic events of 12% (95% CI, 10–15), 26% (95% CI, 22–30), and 44% (95% CI, 39–50) after…”
BackgroundSolid Phase Assays for Antiphospholipid Antibodies
Devreese, K. M. J. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1744364 · Cited by 28
Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome
Vikerfors, A., Svenungsson, E., Ågren, A., Mobarrez, F., Bremme, K. A., Holmström, M., Eelde, A., Bruzelius, M., Elgue, G., Wallén, H., et al. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.02.023 · Cited by 26
“belonged to the triple positive entity previously described to have a high thrombotic risk [32].”
BackgroundAnticoagulating patients with high-risk acquired thrombophilias
Skeith, L. (2018) · Blood · doi:10.1182/blood-2018-05-848697 · Cited by 26
“1% per personyear, which is in keeping with previous studies.(30,31) This study provides additional evidence in favor of long-term anticoagulation as well as laboratory screening in patients who present with unprovoked VTE, especially if they are otherwise deemed to be at low risk of VTE recurrence and are planning to…”
ResultAPS – controversies in diagnosis and management, critical overview of current guidelines
Pengo, V. (2011) · Thrombosis Research · doi:10.1016/s0049-3848(11)70014-7 · Cited by 25
“Patients with triple positive tests (all the three tests are positive) have a very significant association with thrombosis and pregnancy loss [3,8] and high recurrence rate in the follow up period despite antithrombotic treatment [9].”
BackgroundSelf-citation
Metadata
- Authors
- PENGO, V., RUFFATTI, A., LEGNANI, C., GRESELE, P., BARCELLONA, D., ERBA, N., TESTA, S., MARONGIU, F., BISON, E., DENAS, G., BANZATO, A., PADAYATTIL JOSE, S., & ILICETO, S.
- Affiliations
- University of Padua (IT)
- University of Bologna (IT)
- University of Perugia (IT)
- University of Cagliari (IT)
- Corresponding author
- PENGO, V.
- ORCID
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 8
- Issue
- 2
- Pages
- 237-242
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W2119266650
- Cited by
- 632
- References
- 39
- Citations by year
- 2026: 37 · 2025: 31 · 2024: 40 · 2023: 47 · 2022: 52 · 2021: 45 · 2020: 55 · 2019: 50 · 2018: 41 · 2017: 33 · 2016: 38 · 2015: 35 · 2014: 32 · 2013: 30 · 2012: 30
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thrombosis and Haemostasis (publishedVersion)
- PubMed (publishedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- antiphospholipid syndrome, triple positivity, lupus anticoagulant, anticardiolipin antibodies, anti-beta2-glycoprotein I antibodies, venous thromboembolism, arterial thromboembolism, pregnancy morbidity, catastrophic antiphospholipid syndrome, oral anticoagulation, thromboembolic recurrence, major bleeding, cardiovascular mortality
- MeSH terms
- Administration, Oral, Adult, Aged, Anticoagulants, Catastrophic Illness, Female, Hemorrhage, Humans, Italy, Male, Middle Aged, Predictive Value of Tests, Pregnancy, Pregnancy Complications, Cardiovascular, Recurrence, Retrospective Studies, Risk Factors, Time Factors, Biomarkers, Incidence, Proportional Hazards Models, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Treatment Outcome, Antibodies, Antiphospholipid, Antibodies, Anticardiolipin, Disease Progression, Risk Assessment, Kaplan-Meier Estimate, beta 2-Glycoprotein I, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
